Aclidinium
- TRADE NAME: Tudorza Pressair (Forest)
- INDICATIONS: Long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema
- CLASS: Anticholinergic, Muscarinic antagonist
- HALF-LIFE: 5–8 hours
FDA APPROVAL DATE: 07/30/2012
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Anticholinergics
PREGNANCY CATEGORY: C
Please login to see the rest of this drug profile
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric